Media.Player

Method to Enrich for Cells Transduced with Chimeric Antigen Receptors

技術優勢

Selective stimulation of CAR-transduced T cells but not non-transduced T cellsSelective expansion of CAR-transduced T cellsExpansion of selectively transduced cells to get the same number of transduced cells without expanding non-transduced cellsRapid enrichment of CAR-transduced T cells

技術應用

CAR T cell therapies

詳細技術說明

Dr. Otto Yang and colleagues in the Department of Microbiology, Immunology & Molecular Genetics at UCLA have developed a method of specifically expanding CAR-transduced T cells, without inducing expansion of the total T cell population. This method was developed to stimulate proliferation of the CAR-transduced T cells but not the non-transduced T cells, leading to selective expansion of CAR-transduced T cells and therefore rapid enrichment.

*Abstract

Researchers at UCLA have developed a method to expand chimeric antigen receptor-transduced T cells for use in immunotherapies.

*Applications

• CAR T cell therapies

*Principal Investigation

Name: Ayub Ali

Department:

Name: Irvin S.Y. Chen

Department:

Name: Scott Kitchen

Department:

Name: Hwee Ng

Department:

Name: Otto Yang

Department:

Name: Jerome Zack

Department:

其他

State Of Development

Dr. Otto Yang and colleagues have shown proof-of-concept experiments demonstrating rapid enrichment of CAR-transduced cells despite a relatively low starting transduction rate.

Background

Chimeric Antigen Receptors (CAR) T cells are promising therapeutics for the treatment of cancer and are also being considered for the treatment of infectious diseases. However, adoptive transfer and clinical manufacturing of CAR T cells is a time-consuming, complex, and labor-intensive process. A key issue with CAR-engineered T cell therapies (and cell therapies, in general) is the low transduction efficiency of T cells with CAR-expressing constructs. For instance, peripheral blood T cells that are often the target of CAR gene therapy typically have transduction efficiencies less than 50%, often 10-20%. As a result, production of sufficient cell numbers for therapy requires an increase in the scale of patient cell collection as well as more extensive ex vivo T-cell selection and expansion. This contributes to CAR T cell therapies high manufacturing costs. Thus, there is a clear need for technologies that can optimize the transduction efficiency and manufacturing of CAR T cells.

Additional Technologies by these Inventors

• Covalent Bi-Specific Monoclonal Antibodies that Expand Selective T Cell Subsets
• Approach For Efficient Protein Incorporation Into Recombinant Vaults

Tech ID/UC Case

25777/2016-255-0

Related Cases

2016-255-0

國家/地區

美國